Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca unveils second brand play in India

This article was originally published in Scrip

Executive Summary

AstraZeneca appears to be the latest to join a clutch of foreign firms deploying the second-brand approach to penetrate the Indian market more effectively.

You may also be interested in...



Eisai-Mylan Tango for Second Halaven Brand In India But Eyes On Pricing, Generics

Eisai has struck a deal with Mylan for a second brand of Halaven in India, joining a growing list of foreign firms deploying this approach to expand access to novel therapies in the country amid emerging competition.

AZ's Brilinta Patents 'Vulnerable' To Challenge In India

An Indian court has lifted restraining orders against Micro Labs, Dr Reddy’s and Natco and held that they have made a “strong credible challenge” to the validity of AstraZeneca’s patents for Brilinta in the country. The UK firm has appealed the order.

AstraZeneca Seeks To Ward Off Brilinta Patent Infringer In India

An Indian court has blocked an alleged infringer of AstraZeneca's patent pertaining to Brilinta (ticagrelor), but the case, some experts claim, also brings to the fore certain controversial tactics at play in the legal arena as large firms pursue litigation to safeguard their intellectual property.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC028884

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel